Imprime PGG：大腸癌治療薬市場分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Clinical Staging 15
3.3 Symptoms 16
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Screening and Diagnosis 18
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.1.3 Clinical Practice 25
5 Competitive Assessment 32
5.1 Overview 32
6 Unmet Need and Opportunity 34
6.1 Overview 34
6.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients 35
6.2.1 Unmet Need 35
6.2.2 Gap Analysis 37
6.2.3 Opportunity 37
6.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients 39
6.3.1 Unmet Need 39
6.3.2 Gap Analysis 40
6.3.3 Opportunity 40
6.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease 41
6.4.1 Unmet Need 41
6.4.2 Gap Analysis 42
6.4.3 Opportunity 42
6.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients 43
6.5.1 Unmet Need 43
6.5.2 Gap Analysis 43
6.5.3 Opportunity 44
7 Pipeline Assessment 45
7.1 Overview 45
7.2 Promising Drugs in Clinical Development 46
8 Imprime PGG 48
8.1 Overview 48
8.2 Efficacy 49
8.3 Safety 50
8.4 Dosing and Formulation 50
8.5 Potential Clinical and Commercial Positioning 51
8.6 SWOT Analysis 52
8.7 Forecast 53
9 Appendix 54
9.1 Bibliography 54
9.2 Abbreviations 59
9.3 Methodology 63
9.4 Forecasting Methodology 63
9.4.1 Diagnosed Colorectal Cancer Patients 63
9.4.2 Percent Drug-Treated Patients 64
9.4.3 General Pricing Assumptions 64
9.4.4 Average Body Weight and Surface Area Across the 8MM 65
9.4.5 Generic Erosion 65
9.4.6 Pricing of Pipeline Agents 65
9.5 Primary Research – KOLs Interviewed for this Report 66
9.6 Primary Research – Prescriber Survey 67
9.7 About the Authors 68
9.7.1 Analyst 68
9.7.2 Global Head of Healthcare 69
9.8 About GlobalData 70
9.9 Disclaimer 70